A 15% surge in a single day, BBIO's billion-yuan funding and valuation cliff

NEXT PICK · Market Insights

A 15% surge in a single day, BBIO's billion-yuan funding and valuation cliff

Thursday, July 9, 2026

How did a biopharmaceutical stock, which is still losing hundreds of millions of dollars annually with earnings per share of negative $3.74, soar 15.12% in a single trading day, pushing the price to $90.17 and increasing trading volume to nearly six times the daily average over the past three months?

The answer isn't a whim of money, but two solid blows falling at the same time: positive data from the phase 3 clinical trial of the oral drug infigratinib, and a new financing round of up to $1 billion with a conversion price premium exceeding 100%.

When the market reprices a company in a single day, should you chase it or ask—has this euphoria already been paid for in advance?

Latest price $90.17 ▲ +15.12%

Market capitalization Approximately $17.6 billion ▲ Holding above the moving average

Earnings per share -$3.74 ▼ Still operating at a loss

A company that turns 'rare diseases' into an assembly line

BridgeBio was founded in 2015 and headquartered in Palo Alto, California, engaging in a business others don't want to touch—drug development for hereditary rare diseases. Its commercial engine is the FDA-approved oral drug Attruby (generic name acoramidis) in 2024, used to treat transthyrin protein-mediated amyloid cardiomyopathy (ATTR-CM).

This engine is roaring. Attruby contributed $362.4 million in net product revenue in 2025, and entering the first quarter of 2026, total quarterly revenue has reached $194.5 million, with Attruby's net sales in the US totaling $180.6 million. By the end of 2025, there had been a total of 6,629 independent patient prescriptions and 1,632 prescribing doctors—this is not just a concept, but real prescription slips written in the clinic.

Its irreplaceability comes from two sources

First, as a new generation "near-complete" TTR stabilizer, Attruby offers adherence advantages over oral administration compared to competitors; Second, the depth of the rare disease pipeline behind it—chondral hypoplasia, limb-and-girdle muscular dystrophy, Canavan disease, hypoparathyroidism—with multiple first-in-class candidates simultaneously in phase III clinical trials.

If most biotech companies buy a lottery ticket, BridgeBio is more like holding five tickets with different numbers at once, plus one that has already won and is cashing out. The only question is: with four cards left, how many can you win?

A 20-fold price-to-sales ratio—is it a moat or a fear of heights?

Let's look at the contrast first

A company still operating large losses with earnings per share of -$3.74 has reached a market value of about $17.6 billion. Using the verified annualized revenue for the first quarter, the price-to-sales ratio exceeds 20 times, far above the common range of 8 to 12 times in the biopharmaceutical industry.

This premium is not buying current profits, but future imagination. The market is betting that Attruby will ramp up and become a multi-billion-dollar blockbuster, plus several third-phase projects in the pipeline are gradually being realized. The valuation assessment given by the report is "stretched," with a reasonable range ranging from $6 billion to $25 billion—a shockingly wide range, all depending on how the pipeline gambles flip the market.

The underlying tone of cash flow is even colder. The company's free cash flow remains deeply negative, with all income reinvested in R&D and commercialization, no dividends, no safety cushion, relying solely on the capital market for continuous funding. Fortunately, the $1 billion funding just launched in early July has pushed away the immediate worry of running out of ammunition.

So here's the question

When a company's valuation is almost entirely betting on "things that haven't happened yet," today's 15% surge is a value discovery, or is it just prematurely feeding the good news of the next three years into today's price?

Standing at a critical validation stage for scaling up commercialization

The report positions BridgeBio in the "commercialization pilot" stage (commercial_pilot), with a clear logic: Attruby has been approved, scaled up, and has generated real revenue, proving the sales mechanism is truly operating rather than just a concept stuck in a PowerPoint presentation. The operating loss ratio is also continuously narrowing, and the explosive growth on the revenue side is squeezing out positive operating leverage.

But it is still far from being "mature"—no positive P/E ratio, no stable free cash flow, no dividends, and valuations rely entirely on pipeline expectations. The market's stance is written on the moving average: the stock price is $90, far above the $69 50-day moving average and the roughly $69 200-day moving average, and trend money clearly agrees with this round of repricing.

However, the steeper the moving average, the greater the pullback gap. The market voted with its feet today, saying "I believe," but if any third-phase data falls short of expectations, will that trust be withdrawn within a day?

Fighting for territory in the shadow of the giants

BridgeBio is not facing a blank market, but a group of financially strong competitors. In the ATTR-CM battlefield, Pfizer's Tafamidis (Vyndamax/Vyndaqel) is the first approved oral TTR stabilizer, with annual sales reaching billions of dollars, dominating with its extensive cardiology specialty sales network; Alnylam's vutrisiran, on the other hand, is closely following with quarterly subcutaneous RNAi therapy.

Other fronts are just as crowded. In the field of chondrodysplasia, BioMarin's Voxzogo has long been approved for market launch; In the gene therapy track for Canavan's disease, CRISPR players like Intellia are eyeing the scene; After acquiring Alexion, AstraZeneca has also expanded into the rare disease map. Most of these competitors have mature products, well-established business networks, and overwhelming financial strength.

BridgeBio's trump card is Attruby's "nearly completely stable" differentiation mechanism combined with pipeline thickness. But the moat is only moderate—it can take a niche spot, but can't withstand the direct crushing of the giants. So the real question isn't "does it have a moat?" but "Is this moat deep enough to support a 20-fold sales-to-sales ratio?"

The ceiling is high enough, but you have to climb layer by layer

Stacking the market space of each pipeline is truly enticing. ATTR-CM is the core battleground, with a global accessible market (TAM) worth billions of dollars, and a large number of patients remain undiagnosed. With the popularization of imaging diagnostic technology, penetration still has room to improve; As a new entrant, Attruby's peak available market value within five years is expected to reach hundreds of millions of dollars.

Expanding further, indications such as achondroplasia, LGMD2I, Canavan disease, and hypoparathyroidism each represent small pools worth hundreds of millions to billions of dollars. Taken together, if the entire pipeline is successfully realized, the potential for peak revenue is considerable, which is precisely the underlying support for current high valuations.

But a high ceiling doesn't mean you can climb up. Each floor must be connected frame by frame using three phases of data, regulatory approvals, and commercial execution—the prices the market offers today already assume it can climb quite high floors.

The confidence of the bulls: data, cash, and pipelines all working together

The bullish logic was ignited in today's big bullish candle—the catalyst is not "expectation," but "has already happened":

▲ Bull Case

Bears' cold water: The good news may have been drained

The bearish side does not deny the positive news but reminds that these positive factors may have been almost fully consumed by today's prices.

▼ Bear Case

What to watch next: the continuous exam from submission to listing

Today's two catalysts have already exploded, but the story is far from over; the pace ahead is dominated by several clear time windows:

•	infigratinib: Plans to submit new drug application to FDA in Q3 2026 and marketing application to EMA in the second half, aiming for U.S. market launch in the first half of 2027 (positive direction, execution is key)
•	Attruby's full-year sales verification: Whether quarterly sales data in 2026 can sustain volume growth directly determines whether high valuations can hold (high impact)
•	Other pipeline readings: Encalert (ADH1), BBP-418 (LGMD2I), and other three phases have been read one after another, each positive signal being a new upward engine (high impact).
•	Phase I/II data for BBP-812 (Canavan disease) gene therapy have been updated, indicating moderate impact option value

From $17 to $90, a history of expectation reversals

BridgeBio was listed on Nasdaq in June 2019 at $17 per share. In the following years, it experienced a typical biotech roller coaster: in 2021, early pipeline data pushed it above $70, but then pulled back after the market ran out of patience; During the 2022-2023 rate hike cycle, valuations in the entire biopharmaceutical sector were compressed, and it once fell below $10.

The turning point came in 2024—Attruby received FDA approval, and the company transitioned from a "cash-burning concept" to a "commercialized company with revenue," marking a new round of stock price gains. Entering 2025 and 2026, Attruby's volume has far exceeded the market's early cautious expectations, with staggering gains over the past 12 months, and its stock price has revalued all the way to today's $90 level.

Looking back, the market's judgment is mixed: the optimism of 2021 was dashed, but Attruby's commercialization success far exceeded conservative expectations. The only lesson in history is—high expectations are a double-edged sword. Today, pipeline expectations are also high, and if any data falls short of expectations, a pullback can repeat itself at any time.

⚠️ Risk Notice • If any Phase III clinical trial fails, both the pipeline value and the stock price will shrink simultaneously • With a price-to-sales ratio exceeding 20 times, valuation compression risks are huge if sales fall short of expectations • Free cash flow remains negative, financing is still needed in the future, and equity dilution is inevitable • Giants like Pfizer and Alnylam are fiercely competitive, and market penetration remains uncertain • Today's positive news may have already been significantly priced in, and chasing highs in the short term can easily trap you at high levels

🟡 Neutral The positive news is solid, but the gains have already exceeded some expectations, and the betting game has not fully flipped.

💬 Discussion Conclusion: The fundamentals are positive, but chasing higher prices at a 20x price-to-sales ratio carries considerable risk. It now has real-time buy and sell prices and signals, and BBIO is posted on the official WeChat account for viewing.

Data source

•	Source: NextPick real-time snapshot + BridgeBio earnings report and press release + SEC 8-K announcement + mainstream financial media coverage. Key data (latest stock price, market capitalization, Attruby revenue, $1 billion financing, infigratinib phase III data) have all been cross-verified.